Petrelintide for weight management in adults with overweight or obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 trial compares petrelintide to placebo in adults with overweight or obesity who have at least one weight-related condition and have not had Type 2 Diabetes. All participants follow a reduced-calorie diet and increased physical activity as part of standard weight-management guidance. The study will monitor weight loss and safety outcomes over time to determine if petrelintide provides additional benefit beyond lifestyle changes. Eligible participants must have BMI ≥30, or BMI ≥27 with a weight-related comorbidity, and prior unsuccessful weight-loss attempts. Key exclusion criteria include diabetes, prior amylin analog treatment, and diabetes-range HbA1c at screening.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbidity
* History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion Criteria:

* HbA1c ≥ 48 mmol/mol (6.5%), measured by the central laboratory at screening
* Known history of Type 1 or Type 2 diabetes mellitus
* Current or previous treatment with petrelintide or any other amylin analog

Where it's running

• Pinnacle Research Group
  Anniston, Alabama, United States Recruiting
• CMR of Greater New Haven, LLC
  Hamden, Connecticut, United States Recruiting
• Suncoast Clinical Research
  New Port Richey, Florida, United States Recruiting
• Progressive Medical Research
  Port Orange, Florida, United States Recruiting
• Solaris Clinical Research (SCR)
  Meridian, Idaho, United States Recruiting
• Rochester Clinical Research, Inc
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Reference Study ID Number: CC46368 https://forpatients.roche.com/No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. and Canada)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Petrelintide for weight management in adults with overweight/obesity and type 2 diabetes

  This study tests whether petrelintide, added to a reduced-calorie diet and more physical activity, helps people with overweight or obesity and type 2 diabetes lose weight more effectively than a placebo.

  Recruiting at 2 sites Phase 3 Hoffmann-La Roche · Los Angeles, California and 1 other locations · NCT07843485

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• AZD6234: a new weekly shot to help adults lose weight

  This Phase 3 trial tests whether AZD6234 helps adults with obesity or overweight and weight-related health issues lose weight compared to placebo.

  Recruiting at 76 sites Phase 3 AstraZeneca · Dothan, Alabama and 219 other locations · NCT07784725

• AZD6234: a new option for adults with type 2 diabetes and excess weight

  A phase 3 trial tests whether AZD6234 helps adults with type 2 diabetes and overweight or obesity more than placebo over about 68 weeks.

  Recruiting at 58 sites Phase 3 AstraZeneca · Fairhope, Alabama and 229 other locations · NCT07784270

• AZD6234 added to current diabetes therapy to help with weight loss in adults who are overweight or have obesity

  This study tests whether AZD6234, when added to a person’s current incretin-based weight management therapy, can help adults with obesity or overweight lose more weight than a placebo over about 68 weeks.

  Recruiting at 56 sites Phase 3 AstraZeneca · Escondido, California and 95 other locations · NCT07776509

• Switching GLP-1 RA to Maridebart Cafraglutide in Adults with Obesity or Overweight

  This study tests whether switching from a GLP-1 receptor agonist to maridebart cafraglutide is safe and tolerable for adults who are overweight or obese.

  Recruiting at 56 sites Phase 3 Amgen · Pelham, Alabama and 56 other locations · NCT07575399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.